Patient Care Online: FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis
Patient Care Online: FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis by Patient Care Editorial Staff NEWS PROVIDED BY Alphyn Biologics February 20, 2025 The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application submitted by Alphyn Biologics for Zabalafin Hydrogel, a topical therapy intended for the treatment…